# 2025年11月24日 - 专业文献速递

本期速递为您整理了最新的科研文献及AI评价，每一篇文献都包含了详细的元数据、原文摘要、中文翻译和AI的专业点评，敬请参考。

---

## 1. 评估心率和呼吸频率测量误差对预测经鼻高流量氧疗结局能力的影响：一项多中心研究

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41275299](https://pubmed.ncbi.nlm.nih.gov/41275299)
**期刊：** Critical care (London, England)
**PMID：** 41275299
**DOI：** 10.1186/s13054-025-05765-1

### 第一部分 原文与翻译

**英文原标题：** Evaluating the effect of heart and respiratory rate measurement errors on the ability to predict the outcome of high flow nasal cannula therapy: a multi-centre study.

**英文摘要原文：**
BACKGROUND: The respiratory rate oxygenation (ROX) index, and machine learning (ML) models, are promising approaches to help clinicians identify earlier those patients at risk of failing high flow nasal cannula (HFNC) therapy. Respiratory rate (RR) and heart rate (HR) are key inputs to these models, but their measurement in a hospital environment may be subject to significant errors. The effect of these errors on the accuracy of HFNC outcome predictions is currently unknown.

METHODS: We evaluated the capability of a recently-proposed ML model called Tabular Prior-data Fitted Network (TabPFN), a range of standard ML models, and the ROX index and its variants, to predict the outcome of HFNC therapy using measurements made within the first 2 h of treatment in patients with acute hypoxemic respiratory failure. 596 AHRF patients receiving HFNC (456 successes, 140 failures) from the RENOVATE trial in Brazil were used for model training. External validation was performed on a dataset on 241 AHRF patients (156 successes, 85 failures) from Italy and the US. During training and testing, we replicated RR and HR measurement errors that were consistent with those recorded in previously published studies employing 30-second and 15-second manual counting time-windows, respectively, and employed bootstrapping and Monte Carlo simulation to evaluate their effects on the accuracy of outcome predictions.

RESULTS: The TabPFN model was more affected by the RR and HR measurement errors, but still provided more accurate predictions of HFNC outcome (Mean [95% CI] Accuracy 0.79 [0.73-0.84], AUC 0.86 [0.82-0.89] in external validation) than the ROX index and its variants (Accuracy 0.71 [0.68-0.75], AUC 0.78 [0.75-0.80]). Augmenting patient datasets with arterial blood gas measurements further improved the performance and robustness of the TabPFN model, but not the ROX index.

CONCLUSIONS: In this multi-centre study, the recently introduced TabPFN ML model outperformed currently available methods for predicting the outcome of HFNC therapy even when realistic levels of measurement errors were included in the clinical data on RR and HR. The predictive performance of this ML model can be further improved by minimizing measurement errors using more advanced monitoring, and/or by additionally using arterial blood gas measurements.

**中文摘要译文：**
背景：呼吸频率氧合（ROX）指数和机器学习（ML）模型是两种有前景的方法，可帮助临床医生更早地识别有经鼻高流量氧疗（HFNC）失败风险的患者。呼吸频率（RR）和心率（HR）是这些模型的关键输入参数，但它们在医院环境中的测量可能存在显著误差。这些误差对HFNC结局预测准确性的影响目前尚不清楚。

方法：我们评估了一种新近提出的名为“表格化先验数据拟合网络”（TabPFN）的机器学习模型、一系列标准机器学习模型以及ROX指数及其变体，在使用急性低氧性呼吸衰竭患者治疗前2小时内的测量数据预测HFNC治疗结局的能力。来自巴西RENOVATE试验的596名接受HFNC治疗的急性低氧性呼吸衰竭（AHRF）患者（456名成功，140名失败）的数据被用于模型训练。外部验证则在一个包含来自意大利和美国的241名AHRF患者（156名成功，85名失败）的数据集上进行。在训练和测试过程中，我们分别复制了与先前已发表研究中采用30秒和15秒手动计数时间窗所记录的RR和HR测量误差相一致的误差，并采用自助法（bootstrapping）和蒙特卡洛模拟来评估这些误差对结局预测准确性的影响。

结果：TabPFN模型受RR和HR测量误差的影响更大，但其对HFNC结局的预测准确性（外部验证中的平均准确度[95% CI]为0.79 [0.73-0.84]，AUC为0.86 [0.82-0.89]）仍高于ROX指数及其变体（准确度为0.71 [0.68-0.75]，AUC为0.78 [0.75-0.80]）。使用动脉血气测量值增强患者数据集进一步提升了TabPFN模型的性能和稳健性，但对ROX指数无此效果。

结论：在这项多中心研究中，即使在RR和HR的临床数据中包含了符合实际水平的测量误差，新近引入的TabPFN机器学习模型在预测HFNC治疗结局方面的表现仍优于当前可用的方法。通过使用更先进的监测技术以最小化测量误差，和/或额外使用动脉血气测量值，可以进一步提高该机器学习模型的预测性能。

### 第二部分 AI 大师评价

该研究直面临床实践中的一个核心痛点——生命体征测量误差，系统评估了其对预测经鼻高流量氧疗（HFNC）结局模型准确性的影响。研究创新性地引入并验证了新型机器学习模型（TabPFN），并证实即使在模拟真实世界测量误差的情况下，其预测性能仍显著优于传统的ROX指数。此项多中心研究不仅为HFNC失败风险的早期预警提供了更可靠的工具，也强调了数据质量的重要性，并指出了通过优化监测技术和融合动脉血气等多维数据来进一步提升模型性能的明确方向，具有重要的临床转化潜力。

---

## 2. 整合全基因组与转录组测序阐明异构体变异的遗传结构

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41274869](https://pubmed.ncbi.nlm.nih.gov/41274869)
**期刊：** Nature communications
**PMID：** 41274869
**DOI：** 10.1038/s41467-025-64336-8

### 第一部分 原文与翻译

**英文原标题：** Integrating whole genome and transcriptome sequencing to characterize the genetic architecture of isoform variation.

**英文摘要原文：**
We present a whole-blood isoform ratio QTL (irQTL) resource by analyzing genome-wide isoform-to-gene expression ratios using sequencing data. In Framingham Heart Study (FHS, n = 2622) discovery, we identify over 1.1 million cis-irQTLs (minor allele frequency [MAF] ≥ 0.01, ±1 Mb of 10,883 isoform transcripts, P < 5 × 10) across 4,971 genes. Among 11,425 sentinel cis-irQTLs, 72% replicate (P < 1 × 10) in the Women's Health Initiative (WHI; n = 2005). Notably, 20% of cis-irQTLs have no significant association with overall gene expression, indicating isoform-specific regulation. These variants are enriched at splice donor/acceptor sites and genome-wide association study loci (P < 1 × 10). We also identify 1870 sentinel trans-irQTLs (MAF ≥ 0.01, P < 1.5 × 10) for 1,084 isoforms across 590 genes, and 2327 rare cis-irQTLs (0.003 < MAF < 0.01) for 2467 isoforms of 1428 genes in FHS, with external replication rates of 61% and 41% in WHI, respectively. We highlight rs12898397 in ULK3, which alters splice site usage and reduces expression of a full-length isoform. Mendelian randomization supports a causal role between this isoform shift and reduced diastolic blood pressure. These findings highlight the power of irQTL mapping to uncover transcript-specific regulatory mechanisms underlying complex traits.

**中文摘要译文：**
我们通过分析测序数据中的全基因组异构体与基因的表达比率，提供了一个全血异构体比率数量性状基因座（irQTL）资源。在弗雷明汉心脏研究（FHS, n = 2622）的发现阶段，我们在4971个基因中鉴定出超过110万个顺式irQTL（cis-irQTLs）（次要等位基因频率 [MAF] ≥ 0.01，位于10883个异构体转录本的±1 Mb范围内，P < 5 × 10⁻⁸）。在11425个前哨顺式irQTL中，72%在妇女健康倡议研究（WHI; n = 2005）中得到重复验证（P < 1 × 10⁻⁶）。值得注意的是，20%的顺式irQTL与基因总体表达水平无显著关联，这表明存在异构体特异性的调控机制。这些变异在剪接供体/受体位点和全基因组关联研究位点中富集（P < 1 × 10⁻¹⁰⁰）。我们还在FHS研究中鉴定出1870个前哨反式irQTL（trans-irQTLs）（MAF ≥ 0.01，P < 1.5 × 10⁻¹¹），涉及590个基因的1084种异构体；以及2327个罕见顺式irQTL（0.003 < MAF < 0.01），涉及1428个基因的2467种异构体，它们在WHI研究中的外部重复验证率分别为61%和41%。我们重点分析了ULK3基因中的rs12898397，该变异改变了剪接位点的使用，并降低了一个全长异构体的表达。孟德尔随机化分析支持了这种异构体转换与舒张压降低之间的因果关系。这些发现凸显了irQTL图谱分析在揭示复杂性状背后转录本特异性调控机制方面的强大能力。

### 第二部分 AI 大师评价

本研究通过整合大规模人群的全基因组与转录组测序数据，旨在系统性地鉴定并描绘影响基因异构体相对表达水平的遗传位点（irQTL）。研究团队不仅构建了一个全面的irQTL资源库，还发现大量irQTL（约20%）仅特异性地调控异构体比例而不影响基因总表达量，揭示了基因调控的精细层次。该研究的创新之处在于超越了传统的eQTL分析，聚焦于转录本异构体层面的调控，并通过孟德尔随机化将一个具体的异构体转换与血压这一复杂性状建立因果关联。这一发现不仅为解析复杂性状的遗传基础提供了新视角和强大工具，也为理解疾病的分子机制开辟了新路径。

---

## 3. 关于“肾脏替代治疗”的通讯文章

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41273368](https://pubmed.ncbi.nlm.nih.gov/41273368)
**期刊：** Intensive care medicine
**PMID：** 41273368
**DOI：** 10.1007/s00134-025-08223-2

### 第一部分 原文与翻译

**英文原标题：** Correspondence on "Renal replacement therapy".

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无摘要。

### 第二部分 AI 大师评价

本文是一篇关于“肾脏替代治疗”的通讯文章，通常此类文章是针对既往发表的研究进行评论、补充或提出不同见解。虽然该文献没有提供摘要，无法得知其具体讨论内容，但这类学术通讯对于促进学术争鸣、澄清研究细节以及推动特定领域（如此处的重症监护医学）的深入探讨具有重要价值。它本身不提供新的研究数据或发现，其意义在于促进科学对话和对现有证据的审慎评估。

---

## 4. 重新评估开放肺通气在ARDS中的应用：一项针对2023年ESICM指南的更新版Meta分析强调了常规使用的风险并支持个体化策略。

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41273365](https://pubmed.ncbi.nlm.nih.gov/41273365)
**期刊：** Intensive care medicine
**PMID：** 41273365
**DOI：** 10.1007/s00134-025-08214-3

### 第一部分 原文与翻译

**英文原标题：** Reassessing open lung ventilation in ARDS: an updated meta-analysis of the 2023 ESICM guidelines highlights risks of routine use and supports individualized strategies.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无可用摘要。

### 第二部分 AI 大师评价

本研究通过一项更新的Meta分析，旨在重新审视2023年欧洲危重病医学会（ESICM）指南中关于急性呼吸窘迫综合征（ARDS）患者的开放肺通气策略。核心发现指出，常规、非选择性地应用开放肺通气策略可能伴随着潜在风险，挑战了其作为普适性治疗方案的地位。该研究的价值在于，它为临床实践提供了最新的循证医学证据，强调了从“一刀切”转向根据患者具体情况制定个体化通气方案的重要性，对优化ARDS患者的呼吸支持治疗具有重要的指导意义。

---

## 5. 1990-2023年全球、区域和国家成人慢性肾脏病的疾病负担及其归因风险因素：一项针对2023年全球疾病负担研究的系统性分析。

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41213283](https://pubmed.ncbi.nlm.nih.gov/41213283)
**期刊：** Lancet (London, England)
**PMID：** 41213283
**DOI：** 10.1016/S0140-6736(25)01853-7

### 第一部分 原文与翻译

**英文原标题：** Global, regional, and national burden of chronic kidney disease in adults, 1990-2023, and its attributable risk factors: a systematic analysis for the Global Burden of Disease Study 2023.

**英文摘要原文：**
BACKGROUND: Chronic kidney disease (CKD) is common and ranks among the leading causes of mortality and morbidity. This analysis aimed to present global CKD estimates using the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2023 to inform evidence-based policies for CKD identification and treatment.

METHODS: This analysis focused on adults aged 20 years and older over the period 1990 to 2023, from 204 countries and territories. Data sources used were published literature, vital registration systems, kidney failure treatment registries, and household surveys. Estimates of CKD burden, including deaths, incidence, prevalence, and disability-adjusted life-years (DALYs), were produced using a Cause of Death Ensemble model and a Bayesian meta-regression analytical tool. A comparative risk assessment approach estimated the proportion of cardiovascular deaths attributable to impaired kidney function and estimated risk factors for CKD.

FINDINGS: Globally, in 2023, 788 million (95% uncertainty interval 743-843) people aged 20 years and older were estimated to have CKD, up from 378 million (354-407) in 1990. The global age-standardised prevalence of CKD in adults was 14·2% (13·4-15·2), a relative rise of 3·5% (2·7-4·1) from 1990. The region with the highest age-standardised prevalence was north Africa and the Middle East (18·0%; 16·9-19·4). Most people had stage 1-3 CKD, with a combined prevalence of 13·9% (13·1-15·0). In 2023, CKD was the ninth leading cause of death globally, accounting for 1·48 million (1·30-1·65) deaths, and the 12th leading cause of DALYs, with an age-standardised DALY rate of 769·2 (691·8-857·4) per 100 000. Impaired kidney function as a risk factor accounted for 11·5% (8·4-14·5) of cardiovascular deaths. High fasting plasma glucose, body-mass index, and systolic blood pressure were all leading risk factors for CKD DALYs.

INTERPRETATION: CKD is a major global health issue, with rising prevalence and increasing importance as a cause of death and as a risk factor for cardiovascular death. A better understating of aetiology, appropriate screening, and implementation programmes are needed to translate advances in CKD treatment into improved patient outcomes.

FUNDING: Gates Foundation, Wellcome, US National Kidney Foundation, and US National Institute of Diabetes and Digestive and Kidney Diseases.

**中文摘要译文：**
背景：慢性肾脏病（CKD）是一种常见疾病，也是导致死亡和发病的主要原因之一。本分析旨在利用2023年全球疾病、伤害和风险因素负担研究（GBD）的数据，提供全球CKD的估算结果，从而为CKD的识别和治疗提供循证政策依据。
方法：本分析聚焦于1990至2023年间，来自204个国家和地区的20岁及以上成人。所使用的数据来源包括已发表的文献、生命登记系统、肾衰竭治疗登记处和家庭调查。CKD的疾病负担估算，包括死亡数、发病率、患病率和伤残调整生命年（DALYs），是使用死因集成模型和贝叶斯荟萃回归分析工具生成的。采用比较风险评估方法，估算了因肾功能受损导致的心血管死亡比例，并估算了CKD的风险因素。
结果：2023年，全球估计有7.88亿（95%不确定区间 7.43-8.43亿）20岁及以上成人患有CKD，高于1990年的3.78亿（3.54-4.07亿）。全球成人CKD的年龄标化患病率为14.2%（13.4-15.2%），相较于1990年相对上升了3.5%（2.7-4.1%）。年龄标化患病率最高的地区是北非和中东（18.0%；16.9-19.4%）。大多数患者为1-3期CKD，合并患病率为13.9%（13.1-15.0%）。2023年，CKD是全球第九大死因，导致148万（130-165万）人死亡，同时是第十二大致残原因，年龄标化DALY率为每10万人769.2（691.8-857.4）。作为风险因素，肾功能受损导致了11.5%（8.4-14.5%）的心血管死亡。高空腹血糖、高体重指数和高收缩压是导致CKD DALYs的主要风险因素。
结论：CKD是一个严峻的全球性健康问题，其患病率不断上升，并且作为死亡原因和心血管死亡风险因素的重要性日益增加。需要更好地理解其病因，并推行适当的筛查和实施方案，才能将CKD治疗的进展转化为患者结局的改善。
资金来源：盖茨基金会、威康信托基金会、美国国家肾脏基金会以及美国国家糖尿病、消化和肾脏疾病研究所。

### 第二部分 AI 大师评价

本研究基于最新的2023年全球疾病负担（GBD）数据，系统地评估了1990年至2023年间成人慢性肾脏病（CKD）在全球、区域及国家层面的疾病负担和归因风险。研究发现，全球CKD患病人数和年龄标化患病率持续攀升，已成为全球第九大死因，并揭示了高血糖、高体重指数和高血压是其主要风险因素。这项研究的价值在于提供了最全面、最前沿的全球CKD流行病学证据，不仅量化了CKD作为独立疾病和心血管疾病风险因素的巨大影响，也为各国制定针对性的CKD防控策略和资源分配提供了权威的数据支持。

---

## 6. 大剂量流感疫苗在老年人群中预防住院的效果 (FLUNITY-HD)：一项个体层面汇总分析

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41115437](https://pubmed.ncbi.nlm.nih.gov/41115437)
**期刊：** Lancet (London, England)
**PMID：** 41115437
**DOI：** 10.1016/S0140-6736(25)01742-8

### 第一部分 原文与翻译

**英文原标题：** Effectiveness of high-dose influenza vaccine against hospitalisations in older adults (FLUNITY-HD): an individual-level pooled analysis.

**英文摘要原文：**
BACKGROUND: Two large-scale trials comparing high-dose inactivated influenza vaccine (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) against hospitalisation outcomes have been conducted in Denmark and Spain. We aimed to analyse the pooled data from these trials to enhance generalisability and assess the relative vaccine effectiveness (rVE) of HD-IIV versus SD-IIV against severe clinical outcomes in older adults.

METHODS: FLUNITY-HD was a prespecified, individual-level pooled analysis of two methodologically harmonised pragmatic, individually randomised trials comparing HD-IIV with SD-IIV in older adults. DANFLU-2 included adults aged 65 years or older and GALFLU included community-dwelling adults aged 65-79 years. DANFLU-2 was conducted during the 2022-23, 2023-24, and 2024-25 influenza seasons in Denmark, whereas GALFLU was conducted during the 2023-24 and 2024-25 seasons in Galicia, Spain. In both trials, participants were randomly assigned (1:1) to receive either HD-IIV (60 μg of haemagglutinin [HA] antigen per strain) or SD-IIV (15 μg of HA antigen per strain) and followed up for the occurrence of endpoints from 14 days after vaccination to May 31 the following year in each season. Routine health-care databases were used as primary data source. The primary endpoint of both the pooled analysis and the individual trials was hospitalisation for influenza or pneumonia. Secondary endpoints were tested hierarchically, and consisted of hospitalisation for any cardiorespiratory disease, laboratory-confirmed influenza hospitalisation, all-cause hospitalisation, all-cause mortality, hospitalisation for influenza (ICD-10), and hospitalisation for pneumonia. The pooled analysis is registered with ClinicalTrials.gov, NCT06506812.

FINDINGS: The analysis included 466 320 individually randomised participants (233 311 were randomly assigned to HD-IIV and 233 009 to SD-IIV). Mean age was 73·3 years (SD 5·4); 223 681 (48·0%) were female and 242 639 (52·0%) were male. 228 125 (48·9%) participants had at least one chronic condition. The primary endpoint of hospitalisation for influenza or pneumonia occurred in 1312 (0·56%) of 233 311 participants in the HD-IIV group compared with 1437 (0·62%) of 233 009 participants in the SD-IIV group (rVE 8·8%, 95% CI 1·7 to 15·5; one-sided p=0·0082). HD-IIV also reduced the incidence of cardiorespiratory hospitalisation (4720 [2·02%] participants in the HD-IIV group vs 5033 [2·16%] participants in the SD-IIV group; rVE 6·3%, 2·5 to 10·0; p=0·0006), laboratory-confirmed influenza hospitalisation (249 [0·11%] participants vs 365 [0·16%] participants; rVE 31·9%, 19·7 to 42·2; p<0·0001), and all-cause hospitalisation (19 921 [8·54%] vs 20 348 [8·73%]; rVE 2·2%, 0·3 to 4·1; p=0·012). All-cause mortality occurred with similar frequency in both groups (1421 [0·61%] vs 1437 [0·62%]; rVE 1·2%, -6·3 to 8·3; p=0·38). ICD-10-coded hospitalisation for influenza occurred in 164 (0·07%) participants in the HD-IIV group and 271 (0·12%) participants in the SD-IIV group (rVE 39·6%, 26·4 to 50·5) and hospitalisation for pneumonia occurred in 1161 (0·50%) participants in the HD-IIV group and 1187 (0·51%) participants in the SD-IIV group (rVE 2·3%, -6·0 to 10·0). The incidence of serious adverse events was similar between groups (16 032 events in the HD-IIV group and 15 857 events in the SD-IIV group).

INTERPRETATION: In this prespecified pooled analysis, HD-IIV demonstrated superior protection compared with SD-IIV against hospitalisation for influenza or pneumonia and also reduced the incidence of the secondary endpoints of cardiorespiratory hospitalisation, laboratory-confirmed influenza hospitalisation, and all-cause hospitalisation. Given wide eligibility for influenza vaccination, implementing HD-IIV could result in substantial public health benefits.

FUNDING: Sanofi.

**中文摘要译文：**
背景: 丹麦和西班牙已进行两项大规模试验，旨在比较大剂量灭活流感疫苗 (HD-IIV) 与标准剂量灭活流感疫苗 (SD-IIV) 在预防住院方面的效果。本研究旨在对这些试验的数据进行汇总分析，以增强结果的普适性，并评估 HD-IIV 相较于 SD-IIV 在老年人中预防严重临床结局的相对疫苗有效性 (rVE)。

方法: FLUNITY-HD 是一项预设的、个体层面的汇总分析，整合了两项在方法学上协调一致的实用性、个体随机试验，旨在比较 HD-IIV 与 SD-IIV 在老年人中的效果。DANFLU-2 研究纳入了65岁及以上的成年人，而 GALFLU 研究则纳入了居住在社区的65-79岁成年人。DANFLU-2 于2022-23、2023-24和2024-25流感季在丹麦进行，而 GALFLU 则于2023-24和2024-25流感季在西班牙加利西亚进行。在两项试验中，参与者均被随机分配 (1:1) 接受 HD-IIV (每株含60 μg血凝素 [HA] 抗原) 或 SD-IIV (每株含15 μg HA抗原)，并从接种后14天开始随访至次年5月31日，以观察终点事件的发生。常规医疗保健数据库被用作主要数据源。汇总分析及各单项试验的主要终点均为因流感或肺炎住院。次要终点按层级进行检验，包括因任何心肺疾病住院、实验室确诊的流感住院、全因住院、全因死亡、因流感住院 (ICD-10) 以及因肺炎住院。该汇总分析已在 ClinicalTrials.gov 注册，编号为 NCT06506812。

结果: 分析共纳入466,320名个体随机参与者 (233,311人随机分配至 HD-IIV 组，233,009人分配至 SD-IIV 组)。平均年龄为73.3岁 (标准差5.4)；女性223,681人 (48.0%)，男性242,639人 (52.0%)。228,125名 (48.9%) 参与者至少患有一种慢性病。主要终点事件（因流感或肺炎住院）在 HD-IIV 组的233,311名参与者中发生了1312例 (0.56%)，而在 SD-IIV 组的233,009名参与者中发生了1437例 (0.62%) (rVE 8.8%, 95% CI 1.7-15.5; 单侧 p=0.0082)。HD-IIV 还降低了心肺疾病住院 (HD-IIV 组4720例 [2.02%] vs SD-IIV 组5033例 [2.16%]; rVE 6.3%, 2.5-10.0; p=0.0006)、实验室确诊的流感住院 (249例 [0.11%] vs 365例 [0.16%]; rVE 31.9%, 19.7-42.2; p<0.0001) 以及全因住院 (19,921例 [8.54%] vs 20,348例 [8.73%]; rVE 2.2%, 0.3-4.1; p=0.012) 的发生率。两组的全因死亡率发生频率相似 (1421例 [0.61%] vs 1437例 [0.62%]; rVE 1.2%, -6.3-8.3; p=0.38)。ICD-10编码的流感住院在 HD-IIV 组发生164例 (0.07%)，在 SD-IIV 组发生271例 (0.12%) (rVE 39.6%, 26.4-50.5)；肺炎住院在 HD-IIV 组发生1161例 (0.50%)，在 SD-IIV 组发生1187例 (0.51%) (rVE 2.3%, -6.0-10.0)。两组的严重不良事件发生率相似 (HD-IIV 组16,032例事件，SD-IIV 组15,857例事件)。

解读: 在这项预设的汇总分析中，与 SD-IIV 相比，HD-IIV 在预防因流感或肺炎住院方面表现出更优越的保护效果，并降低了心肺疾病住院、实验室确诊的流感住院以及全因住院等次要终点的发生率。鉴于流感疫苗接种的广泛适用性，推广使用 HD-IIV 可能会带来显著的公共卫生效益。

资金来源: Sanofi.

### 第二部分 AI 大师评价

本研究通过对两项欧洲大型随机对照试验的个体数据进行汇总分析，旨在精确评估大剂量流感疫苗相较于标准剂量疫苗在老年人中预防住院的相对有效性。研究的关键发现是，大剂量疫苗在降低因流感/肺炎、心肺疾病、实验室确诊流感及全因住院风险方面均表现出显著优势。这项研究以其近五十万人的庞大样本量和高质量的证据，为全球优化老年人群流感疫苗接种策略提供了强有力的支持，具有重大的公共卫生价值和临床指导意义。

---

速递结束，祝您工作愉快！